The recent inclusion of disruptive mood dysregulation disorder (DMDD) in the DSM-5 can improve treatment for chronically irritable children, who may have been diagnosed in the past with bipolar disorder.
Pediatric visits for bipolar disorder in the United States skyrocketed from 25 per 100,000 in 1994-95 to 1,003 per 100,000 in 2002-2003. As a result, many of these children were treated with atypical antipsychotic medication.
This may not have been the best treatment, considering many of them may not have even had the disorder, according to Amy K. Roy, PhD, of the Department of Psychology at Fordham University, Bronx, New York, and colleagues
The core feature of DMDD is “chronic, severe persistent irritability” accompanied by temper outbursts for at least three times a week for at least a year. While the symptoms are similar to those of severe mood dysregulation, the difference is that hyperarousal is not included in DMDD.
Part of the problem in treating DMDD is there are no clinical trials to inform clinical practice. However, a first step in treatment would be stimulant medication, Roy, et al, write in the American Journal of Psychiatry, given the class of drugs reduces aggression with minimal side effects. Only if there is no improvement with stimulant and psychosocial treatment should atypical antipsychotics be considered.
“It is…hoped that use of the diagnosis will lead to the identification of a group of highly impaired children for whom targeted interventions can be established, “ the researchers concluded.
Disruptive mood dysregulation disorder (DMDD), a newcomer to psychiatric nosology, addresses the need for improved classification and treatment of children exhibiting chronic nonepisodic irritability and severe temper outbursts. In recent years, many of these children have been diagnosed with bipolar disorder, despite the lack of distinct mood episodes. This diagnostic practice has raised concerns, in part because of the escalating prescription of atypical antipsychotics. This article provides an overview of the limited literature on DMDD, including its history and relevant studies of assessment and treatment. A case study is included to illustrate key points, including diagnostic issues that clinicians may encounter when considering a diagnosis of DMDD.
Enjoying our content?
Thanks for visiting Psychiatry Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Psychiatry Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Evidence-Based Guidance
- Conference Coverage
- Unique Psychiatry Case Studies
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.